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Predicting outcome 
in adults with status 
epilepticus
Status epilepticus (SE) is the most se-
rious and life-threatening form of an 
epileptic seizure because it does not 
end spontaneously and may last for 
hours if not days or weeks depend-
ing on several factors. Repetitive un-
controlled discharges during SE may 
harm neurons and eventually lead to 
neuronal necrosis, apoptosis, and/or 
permanent dysfunction. Thus, imme-
diate and rigorous treatment tailored 
to the individual condition is very im-
portant. In this context, reliable pre-
dictors of SE outcome at an early 
stage of treatment are essential for 
optimal therapy and to avoid under- 
or overtreated SE. The aim of this re-
view is to compile detailed informa-
tion on the validity and reliability of 
several clinical features known to de-
termine outcome in SE.
Introduction
Status epilepticus (SE) represents a het-
erogeneous group of disorders, with a va-
riety of prognoses. The incidence of SE 
ranges from 15–20 per 100,000 per year 
[1]. In patients ≥60 years old, the inci-
dence is almost twice as high as in the 
general population [2]. The mortality 
of a first SE episode in adults is rough-
ly 20% [3]. In 10–40% of SE patients, sei-
zure activity cannot be controlled with 
first-line (benzodiazepines), and second-
line antiepileptic drugs (AEDs; phenyto-
in, valproate, or levetiracetam). This con-
dition—defined as refractory SE (RSE) 
[4]—heralds a prolonged hospitalization 
and worse prognosis than AED-respon-
sive SE [5]. It is usually associated with 
potentially fatal etiologies, severe impair-
ment of consciousness, and with a mor-
tality of almost 40% [6].
Despite the clinical and socioeconom-
ic impact of SE, current knowledge relies 
almost exclusively on retrospective as-
sessments, and the management of RSE 
is supported only by small case series and 
expert opinions. Should patients be treat-
ed aggressively with early intubation and 
high-dose anesthetic drugs, or managed 
less urgently, even when delayed seizure 
control might carry the risk of neuronal 
damage? This decision is complex and 
has been addressed only in a few stud-
ies [7]. A management algorithm which 
fits all different types of SE is not tena-
ble, as morbidity and mortality differs 
considerably in dependence of the un-
derlying causes of SE. Knowledge regard-
ing prognosis and its determining fac-
tors (. Tab. 1) is one of the cornerstones 
for early treatment adaption and tailored 
management algorithms (. Fig. 1).
Determinants of outcome 
in status epilepticus
Etiology of status epilepticus 
and outcome
Estimates of SE and RSE mortality vary, 
as neurofunctional outcome and mortal-
ity mainly depend on the underlying eti-
ology and whether SE following hypoxic–
ischemic encephalopathy is included in 
the study [8]. Therefore, early guidelines 
of the International League Against Ep-
ilepsy (ILAE) proposed a categorization 
of SE according to the underlying etiolo-
gy with the aim to allow comparison be-
tween future epidemiologic and epilepto-
Tab. 1 Determinants of outcome in sta-
tus epilepticus
Demographics and clinical characteristics
Etiology
History of epilepsy
Age
Level of consciousness at status epilepticus    
onset
Status epilepticus characteristics
Seizure type at status epilepticus onset
Duration of status epilepticus
Treatment characteristics
Treatment delay
Adverse events
Complications during status epilepticus
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logic studies on SE [9]. Accordingly, SE 
was classified as
F  acute symptomatic,
F  remote symptomatic,
F  progressive symptomatic, and
F  idiopathic/cryptogenic.
Mortality following SE in patients with 
known epilepsy and insufficient AED lev-
els is low (3%), while it is higher (27%) in 
patients with SE from secondary causes, 
suggesting that the epileptic activity itself 
has no significant contribution to morbid-
ity [10]. With absence SE (ASE), there has 
been no demonstrated fixed deficit, even 
after prolonged SE and in de novo com-
plex partial SE caused by cerebral insults, 
there is little evidence and no consensus 
on seizure-related morbidity [11]. In con-
trast, acute symptomatic etiologies have 
been consistently linked to poor outcome 
[12]. Persistent seizure activity following 
hypoxic–ischemic encephalopathy is an 
independent predictor of poor outcome 
with a mortality of up to 100%, main-
ly because of its largely irreversible brain 
damage [13]. In a recent study on 111 ICU 
patients with RSE, hypoxic–ische mic en-
cephalopathy and brain tumors were in-
dependently associated with high rel-
ative risks (RR) for death (RR 2.41, 95% 
confidence interval [CI] 1.40–4.12 and 
RR 2.81, 95%CI 1.59–4.96) [14]. Regard-
ing brain tumors, different results come 
from a study on the detection and treat-
ment of RSE in the ICU which revealed an 
improvement of the level of consciousness 
in all patients with brain tumors on an-
ticonvulsants [15]. However, the propor-
tion of patients (4%) with brain tumors 
was small.
History of epilepsy and outcome
The majority of SE is thought to develop 
without a prior history of epilepsy [16], 
and almost always secondary to an under-
lying structural or metabolic-toxic pathol-
ogy [17]. In a 5-year observational study 
of 160 ICU patients with SE, epilepsy was 
known and diagnosed prior to SE onset in 
15% [18]. In a prospective study on 154 SE 
patients from 3 sites, seizure history at SE 
onset, a surrogate for no acute and fatal SE 
etiologies, was identified as an indepen-
dent factor for survival in the multivari-
able analysis (odds ratio [OR] for death 
0.23, 95%CI 0.08–0.65) [19].
Age and outcome
Older age has been associated with un-
favorable outcome of SE in many stud-
ies [20]. These studies were contrasted 
by a recent retrospective cohort study of 
106 patients with 111 SE episodes, which 
revealed no significant difference in 
case fatality rate between SE of patients 
younger and older than 70 years but a 
STATUS EPILEPTICUS
At onset
benzodiazepines:
lorazepam*;
phenytoin;
valproic acid
(GCSE and, second-line
only);
levetiracetam*;
lacosamide*;
midazolam*;
propofol*;
combination
of both*?
thiopental
oral AEDs*:
(topiramate*, oxcarbazepine*, pregabalin*)
steroids*
IVIG*/plasmapheresis*
isourane*
ketamine*
(hypothermia), (VNS), (surgery)
phenobarbital, in kids
midazolam*;
clonazepam;
(diazepam)
Favorable
prognosis
Time
i/v-AEDs:
i/v-anesthetics:
midazolam*;
propofol*;
combination
of both*?
i/v-anesthetics:
barbiturate-
anesthesia:
„rescue”-therapies:
immediately after 30-60 min.
REFRACTORY
STATUS EPILEPTICUS
SUPERREFRACTORY
STATUS EPILEPTICUS
Fig. 1 8 Treatment algorithm for status epilepticus. AED antiepileptic drug, GCSE generalized convulsive status epilepticus, 
VNS vagal nerve stimulation, IVIG intravenous immunoglobulines. *Drugs not approved for treatment of status epilepticus
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statistically significant risk for younger 
patients to develop prolonged and more 
severe SE course [21]. Moreover, older 
age was independently associated with a 
more favorable SE course in the multi-
variate analysis. A potential bias in this 
context may have been that a substantial 
proportion of the older age group died 
before reaching the hospital or before 
the diagnosis of SE could be established 
(referral bias). Another explanation may 
be that younger people (1) occasional-
ly develop an “idiopathic” severe SE, la-
beled “malignant SE” and (2) might have 
a higher threshold for SE, which might 
be more difficult to overcome. Further-
more, older patients were probably more 
likely to be sent to the hospital and to be 
admitted to the ICU, even if they were 
not as sick as the younger patients, but 
because they were potentially at greater 
risk to require more rapid and intensi-
fied treatment. However, in a prospective 
multicenter study on 154 SE patients that 
validated the predictive power of a clini-
cal outcome score, older age was identi-
fied as an independent factor for death 
(OR 1.03, 95%CI 1.00–1.06) [19].
Time to treatment of status 
epilepticus and outcome
The question if ongoing epileptic activ-
ity may in some conditions cause brain 
damage and have an effect on outcome 
has been addressed in several studies. 
However, animal models could not pro-
vide a clear answer, as most models have 
been used to investigate the effects of 
SE, by inducing brain insults that cause 
chronic neuronal damage by themselves. 
Models to investigate excitotoxicity have 
used powerful chemoconvulsants or pro-
longed high-frequency repetitive stimu-
lation in nonepileptic animals [22, 23]. 
In humans, there is only little data since 
it would be ethically barely possible to 
conduct a study comparing immediate 
start of treatment with delayed initiation 
of therapy. Retrospective studies may be 
open to several biases and might be ham-
pered by the lack of accurate data ascer-
tainment as the start of SE, especially its 
nonconvulsive forms, often remains un-
detected for a long while and, therefore, 
has to be roughly estimated what impairs 
reliability. A clear relationship between 
duration of SE before administration of 
first-line treatment and response to this 
treatment was observed in a retrospec-
tive single center study of the urban area 
of San Francisco in the 1980s. The dura-
tion of SE in responders was 0.7±0.7 h, in 
nonresponders 1.08±1.41 h—a difference 
that was significant (p=0.05) [24].
Consciousness at the start of 
status epilepticus and outcome
A study which aimed to identify prog-
nostic factors in a hospital-based, adult 
population with SE revealed that at the 
initial evaluation, impairment of con-
sciousness, and older age were predic-
tive of death [25]. A recent study of mor-
tality and recovery from RSE in ICU pa-
tients found that nonsurvivors had sig-
nificant higher levels of consciousness at 
SE onset than survivors (10% awake or 
somnolent vs. 33% awake or somnolent; 
p=0.006)—a relation that was no lon-
ger significant after excluding patients 
with hypoxic–ischemic encephalopathy 
(16% vs. 38%; p=0.072), although NCSE 
in coma remained independently asso-
ciated with death (RR 3.62, 95%CI 1.34–
9.77) [14]. Altered level of consciousness 
in the course of SE or induced by anes-
thetic third-line drugs such as pentobar-
bital, midazolam, propofol, and high-
dose phenobarbital necessitate intuba-
tion, mechanical ventilation. Systematic 
reviews concluded that coma induction 
with barbiturates effectively terminates 
seizures, but delays the recovery from 
coma and prolongs ventilator treatment 
and intensive care [26].
Seizure type at status epilepticus 
onset and outcome
In our study on 111 ICU patients with 
RSE, nonconvulsive SE (NCSE) in coma 
was independently associated with high 
relative risks for death (RR 3.62, 95%CI 
1.34–9.77) [14]—a result which under-
scores the results of previous studies. In 
these studies, patients with complex par-
tial, myoclonic or absence or simple par-
tial seizures showed no association with 
poor outcome, while presence of NCSE 
in coma and generalized convulsive sei-
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Abstract
Status epilepticus (SE) is a life-threatening 
state of persisting or repetitive seizure activi-
ty with often permanent altered level of con-
sciousness. Despite its high morbidity and 
mortality there is no consensus about the 
best strategy to treat specific forms of SE. The 
compromise between the danger related to 
untreated and persistent seizure activity and 
the possible damage induced by unnecessary 
aggressive treatments is challenging. Knowl-
edge about the determinants and reliable 
prediction models of outcome early in the 
course of SE is fundamental for rapid treat-
ment modulation and for planning the level 
of monitoring. This review compiles the cur-
rent evidence for outcome prediction based 
on clinical determinants in adult SE patients.
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Status epilepticus · Mortality · Recovery · 
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Prognosestellung bei 
erwachsenen Patienten 
mit Status epilepticus
Zusammenfassung
Der Status epilepticus (SE) stellt einen lebens-
bedrohlichen Zustand mit einer meist anhal-
tenden oder repetitiven epileptischen Ak-
tivität und persistierenden Vigilanzminder-
ung dar. Trotz der mit SE verbundenen ho-
hen Morbidität und Mortalität gibt es  keinen 
Konsensus bezüglich der besten Behand-
lungsstrategie für die einzelnen Formen von 
SE. Der Kompromiss zwischen der Gefahr ei-
ner anhaltenden, unbehandelten epilepti-
schen Aktivität und der potentiellen Schädi-
gung des Patienten durch unnötig aggressive 
Behandlung bedeutet eine große Herausfor-
derung. Kenntnisse über die prognostisch 
rele vanten Determinanten und über Prädik-
tionsmodelle, die eine frühe prognostische 
Einschätzung erlauben, sind für die rasche 
Behandlungsanpassung und das Ausmaß der 
Patientenüberwachung entscheidend. Diese 
Übersichtsarbeit stellt die wichtigsten Prädik-
tionsmodelle und deren zugrunde liegenden 
klinischen Determinanten für erwachsene SE-
Patienten zusammen.
Schlüsselwörter
Status epilepticus · Mortalität · Erholung · 
Prognose · Neurokritische Behandlung
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zures at SE onset were significantly as-
sociated with high odds for death (OR 
5.80, 95%CI 2.11–15.90). In addition, 
compared with people with a first brief 
unprovoked seizure, the adjusted relative 
risk for death in those with SE was 2.4 
(95%CI 0.9–6.3) over 10 years [20].
A prospective population-based study 
in Richmond, Virgina, found a significant-
ly lower mortality in patients with inter-
mittent SE when compared to those with 
continuous SE (19.6 vs. 31.4%; p<0.001). 
Further analysis revealed a significantly 
and independently increased relative risk 
of death (RR 1.79; p=0.04) in patients with 
continuous SE after adjusting for SE type 
(continuous vs. intermittent), age, etiolo-
gy, and SE duration [27].
Status epilepticus duration 
and outcome
In a 3-year observational study, hospital 
stay increased by 1.13 h with each addi-
tional hour of seizure activity (p=0.02) 
and SE duration was significantly longer 
in patients with unfavorable course of SE 
(defined as death before discharge and/
or RSE). This study was followed by an 
investigation on a cohort of 160 SE pa-
tients which revealed that seizure dura-
tion was significantly longer in patients 
with infections during SE (p<0.0001); 
however, it could not be determined 
whether infections were the cause or the 
result of prolonged seizure activity—a 
limitation of retrospective study design 
[18]. In studies on RSE, seizure duration 
was significantly longer in nonsurvivors 
compared to survivors [28] and seizure 
duration was independently associated 
with high relative risks for death; how-
ever, the relative risk was only minimal 
of every additional hour of SE (for every 
hour: RR 1.001, 95%CI 1.00–1.002) [14]. 
Furthermore, differences in seizure du-
ration between survivors and nonsurvi-
vors tended to be more distinct in pa-
tients with uncontrolled epilepsy in con-
trast to more severe etiologies of SE, such 
as brain tumors and hypoxic–ischemic 
encephalopathy. These findings suggest 
that the impact of seizure duration on 
outcome tends to decrease in the pres-
ence of an underlying, severe etiology of 
SE [14].
Complications during status 
epilepticus and outcome
Complications during the course of SE 
have not been investigated frequently. In 
a study on the incidence of infections dur-
ing SE and their effect on resource utili-
zation [29], infections resulted in a 4-fold 
increase of the use of nursing resources 
and significant prolongation of ICU stay. 
However, further analyses regarding the 
types and influences of infections on SE 
course and outcome, as well as their cor-
relation with time of SE onset, were not 
performed. A study on 160 consecutive SE 
patients revealed that 23% of patients had 
infections during the course of SE [18]—
a similar incidence (24%) as reported by 
a large U.S. cohort study of patients with 
generalized convulsive SE [30]. Of those, 
94% were respiratory tract infections and 
29% were ventilator-associated pneumo-
nias with a predominance in patients with 
NCSE—possibly explained by a higher 
risk of aspiration because of the mostly 
longer period of unrecognized seizure ac-
tivity in patients with altered conscious-
ness compared with patients with convul-
sive SE [31]. The presence of infections 
during SE was significantly associated 
with longer seizure duration (p<0.0001), 
longer ICU stay (p=0.0041), higher risk of 
RSE (OR 4.8; 95%CI 2.8–10.9), and higher 
mortality (OR 5.2; 95%CI 2.11–12.7) [18].
Complications are increasingly recog-
nized in conjunction with the use of an-
esthetic drugs in SE. Phenobarbital and 
pentobarbital were associated with car-
diotoxicity, thiopental with severe hypo-
tension, and propofol with hepatotox-
icity and metabolic acidosis with rhab-
domyolysis and cardiac failure (i.e., pro-
pofol infusion syndrome [32]). A recent 
study of 126 patients with mainly convul-
sive SE revealed an association of the ad-
ministration of continuously adminis-
tered i.v. anesthetic drugs with poor out-
come, while treatment with pentobarbi-
tal was linked to the longest duration of 
mechanical ventilation, and to the high-
est frequency of severe hypotension re-
quiring vasopressors [33]. However, in-
terpretation of these results are imped-
ed by the lack of adjustment for possible 
confounders, such as the fact that phy-
sicians may tend to favor anesthetics as 
a “rescue therapy” in patients with par-
ticular clinical and EEG characteristics 
(confounding by indication). Converse-
ly, prolonged use of i.v. anesthetic drugs 
might be withheld from patients with 
critical medical conditions if their phy-
sicians judge them not to be “fit enough” 
to survive such treatment. Prospective 
studies on more homogenous cohorts 
with patients with RSE treated with non-
sedating 3rd-line AEDs vs. patients with 
i.v. anesthetics as the third drug are need-
ed to strengthen or revoke these results.
Scoring systems
The main goal in the treatment of SE pa-
tients is the early AED administration 
and rapid treatment adaption, tailored to 
the severity of SE and the expected prog-
nosis. One study using the APACHE-II 
score (a prognostic scoring system for 
ICU patients based on underlying dis-
ease, chronic conditions, and physiologic 
variables) for RSE patients, found a high 
initial APACHE-II score to be an inde-
pendent predictor for death [34]. How-
ever, this association was only seen in pa-
tients suffering from RSE.
In 2006 a Swiss study group [35] devel-
oped a scoring system for early outcome 
prediction in SE patients (. Tab. 2). This 
Status Epilepticus Severity Scale (STESS) 
was based on the associations of specific 
Tab. 2 The integral components of the 
Status Epilepticus Severity Score (STESS). 
(Adapted from [35])
Clinical features Score
Level of consciousness at SE onset
Alert or somnolent/confused 0
Stuporous or comatose 1
Worst seizure type at SE onset
Simple partial/complex/absence 0
Generalized convulsive 1
NCSE in coma 2
Age at SE onset
<65 years of age 0
≥65 years of age 2
History of seizures at SE onset
Prior seizures 0
No prior seizures 1
SE status epilepticus, NCSE nonconvulsive status 
epilepticus.
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etiologies, older age, and consciousness 
impairment at SE onset with death and 
a history of survived SE with a decreased 
mortality in SE patients in a prior study 
[25]. STESS promises to provide a ra-
tional for predicting outcome and plan-
ning the level of monitoring and possibly 
modulating the aggressiveness of treat-
ment early in the course of SE [35]. This 
clinical scoring system was validated in a 
prospective multicenter study [19]. How-
ever, one of the sites was the same where 
STESS was generated and the study was 
conducted and analyzed by the same in-
vestigators who developed STESS, pos-
sibly impeding the generalizability of 
their results. Further external and inde-
pendent validation is needed to further 
strengthen the reliability of STESS for 
early outcome prediction.
Clinical practice points
F  To the current knowledge, acute and 
life-threatening etiology (e.g., post-
anoxic encephalopathy, brain tumors, 
herpes encephalitis) is the main factor 
contributing to poor outcome in pa-
tients with SE.
F  Other factors pointing to a worse out-
come seem to be: level of conscious-
ness at SE onset, duration of SE, delay 
of treatment, continuous vs. intermit-
tent SE and complications, especially 
infections.
F  While the influence of older age is 
discussed equivocally, a history of ep-
ilepsy is likely to be associated with a 
favorable outcome.
F  Scores which could be easily and re-
liably assessed at the beginning of SE 
and which would predict outcome 
with high accuracy are highly wel-
come. The so-called STESS score 
hereby seems to be a first step in this 
direction. STESS has been validated 
not only internally, but will also be ex-
ternally in the very near future.
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